[Evaluation of efficacy of cyproterone acetate monotherapy in prostatic cancer].
The trial conducted in the Primorsk Regional Cancer Hospital of Vladivostok and P. A. Herzen Moscow Research Cancer Institute studied effectiveness and tolerance of cyproteron acetate (CA) monotherapy and maximal androgenic block (MAB) (CA + surgical or CA + drug castration). A total of 70 patients with localized, locally advanced and generalized prostatic cancer entered the trial. They were divided into three groups: group 1 (54.3%) patients received CA monotherapy--300 mg/day, group 2 (27.1% patients) was exposed to MAB by surgical castration and received CA in a dose 200 mg/day, group 3 (18.6% patients) were exposed to MAB by drug castration and received 200 mg/day CA. The results obtained show that CA monotherapy and MAB have similar effectiveness in favourable prognostic signs. CA monotherapy was less toxic than CA combination with castratio.
Gurina
L I
LI
Iudin
S V
SV
Rusakov
I G
IG
Bystrov
A A
AA
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D004361:Drug Tolerance; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D017373:Cyproterone Acetate